Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) | PAR 19 209

Opportunity Information: Apply for PAR 19 209

The Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) funding opportunity (PAR 19-209) is a National Institutes of Health (NIH) discretionary grant program in the health category (CFDA 93.855) aimed at accelerating the development of multipurpose prevention technologies (MPTs). The central purpose is to support new, innovative products that can address more than one sexual and reproductive health need at the same time, with an emphasis on preventing HIV infection, preventing pregnancy, and/or preventing other sexually transmitted infections (STIs). The FOA is built around the idea that combining prevention functions into a single product could make protection easier to access and use in real-world settings, which may improve consistent uptake and adherence compared to single-indication tools.

This FOA specifically targets MPT concepts that are on-demand, event-driven, or long-acting, and it allows for both systemic approaches (where active agents act through the bloodstream and broader body distribution) and non-systemic approaches (where activity is more localized, such as within the genital tract). The program scope includes MPTs designed to prevent HIV and pregnancy together, STI and pregnancy together, HIV/STI combinations, and also non-HIV STI-focused MPTs. Importantly, the intended user populations are broad: the FOA supports product development relevant to cisgender and transgender males and females, across all ages, reflecting an inclusive approach to prevention needs and acknowledging that product design and acceptability can vary widely across different groups.

On the research and development side, applications can cover a range of preclinical and translational activities typical of product development pipelines. The FOA calls out pharmacokinetic (PK) and pharmacodynamic (PD) work, safety assessments, and drug-drug interaction (DDI) studies. These efforts can be paired with drug development and formulation science, and may be supported by animal model testing where appropriate. In practice, that means the grant can fund studies that help determine how a candidate product behaves in the body or at the site of action, what dosing strategies may be viable, whether combining agents creates interaction risks, and whether the formulation can reliably deliver the intended protective effect over the desired timeframe (for example, around the time of sex for event-driven options, or over weeks to months for long-acting options).

A notable feature of this opportunity is that it does not treat product performance as purely a biomedical question. The FOA explicitly supports biobehavioral and behavioral/social research to identify user-desired characteristics that affect real-world adoption and continued use. This includes “rheological and biophysical” attributes, essentially the physical properties that influence how a product feels and functions in use, such as texture, viscosity, spreadability, appearance, comfort, perceived effectiveness, perceived safety, and the preferred duration of protection. It also supports studying broader behavioral and social factors that influence whether people choose an MPT, how they integrate it into sexual relationships, what barriers reduce uptake, and what design choices or delivery models could improve acceptance, consistent use, and overall impact.

The funding instrument is an R01 research project grant, and the FOA is labeled “Clinical Trial Optional,” meaning applicants may propose studies that include clinical trials when justified, but a clinical trial is not required for all projects. The eligible applicant pool is wide and includes many kinds of U.S. domestic organizations: state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized governments; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses. The FOA also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, and non-U.S. entities (foreign organizations) and regional organizations, indicating a strong interest in inclusive participation and, where relevant, global or cross-regional collaboration.

Key administrative details from the source include the original closing date of May 6, 2021, and a creation date of March 4, 2019. The listing does not provide an award ceiling or expected number of awards in the provided fields, so applicants would typically look to the full FOA text or NIH program contacts for budget expectations, anticipated award counts, and any institute-specific priorities or constraints. Overall, the opportunity is designed to move promising MPT candidates forward through critical development steps while also investing in the user-centered evidence needed to ensure that next-generation prevention products are not only scientifically viable, but also acceptable and practical for the people they are meant to serve.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2019-03-04.
• Applicants must submit their applications by 2021-05-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 209

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: